On June 20, District Court Judge Paul A. Crotty found U.S. Patent Number 7,846,442 invalid for “obviousness-type double patenting.” The ’442 patent, held by the Mathilda and Terence Kennedy Institute of Rheumatology Trust, allegedly covered the anti-inflammatory drug Humira®. The ruling means AbbVie Inc. will no longer pay licensing fees to produce and market the drug. Finnegan represented AbbVie in this matter.
Justin A. Hendrix
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
James R. Barney
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.